Tymlos Patent Expiration

TYMLOS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748382 RADIUS Method of drug delivery for bone anabolic protein
Oct, 2027

(3 years from now)

US8148333 RADIUS Stable composition comprising a PTHrP analogue
Nov, 2027

(3 years from now)

USRE49444 RADIUS Method of treating osteoporosis comprising administration of PTHrP analog
Apr, 2031

(6 years from now)

US7803770 RADIUS Method of treating osteoporosis comprising administration of PTHrP analog
Apr, 2031

(6 years from now)

US10996208 RADIUS Abaloparatide formulations and methods of testing, storing, modifying, and using same
Apr, 2038

(13 years from now)

US11782041 RADIUS Abaloparatide formulations and methods of testing, storing, modifying, and using same
Apr, 2038

(13 years from now)

US11255842 RADIUS Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHRP) analog
Jan, 2040

(15 years from now)

US11680942 RADIUS Methods for detecting neutralizing antibodies to parathyroid hormone (PTH) and parathyroid hormone-related peptide (PTHrP) analog
Jan, 2040

(15 years from now)



Tymlos is a drug owned by Radius Health Inc. It is used for increasing bone density and reducing fracture risk in postmenopausal women and men with osteoporosis, as well as for detecting neutralizing antibodies. Tymlos uses Abaloparatide as an active ingredient. Tymlos was launched by Radius in 2017. It is is available in solution form for subcutaneous use. Its generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 10, 2040 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 28, 2022
M(M-270) Sep 20, 2024
New Indication(I-907) Dec 19, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ABALOPARATIDE ingredient

NCE-1 date: 28 April, 2021

Market Authorisation Date: 28 April, 2017

Treatment: Method of treating postmenopausal women with osteoporosis at high risk for fracture.; Treatment to increase bone density in men with osteoporosis at high risk for fracture; Use for detecting neutraliz...

Dosage: SOLUTION

How can I launch a generic of TYMLOS before it's drug patent expiration?
More Information on Dosage

TYMLOS family patents

Family Patents